Advertisement
Demo

Merck, Pfizer combo treatment boosts kidney cancer survival

Feb 12, 2019 , Reuters
Drugmaker Merck & Co Inc said on Monday that the combination of its cancer immunotherapy Keytruda with Pfizer Inc's Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with chemotherapy drug Sutent.


Read the full story...


Trending healthcare news keywords at this moment

million research pain ebola digital diabetes finds cancer drug surgery vaccine tip heart study young aha news exercise care viewpoints state highlights proposes lawmakers approves medicare cases -- disease air lung kids severe workers toxic stroke measles adults blood pressure control women risk time sleep training affect brain takes public vaping americans doctors outbreak people linked treatment fda tb graphic patients meds half experts hospital mental hadlima children skyrizi